Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598154 | 0.82 | HRH3 (0.50) | AOC3HRH3 | |
| SCHEMBL28042889 | 0.80 | HRH1 (0.52) | AOC3HRH3 | |
| SCHEMBL14114477 | 0.80 | AOC3 (0.46) | GPR84AOC3HRH3 | |
| SCHEMBL12598153 | 0.79 | AOC3 (0.48) | AOC3HRH3 | |
| SCHEMBL3445980 | 0.79 | — | — | |
| SCHEMBL27772926 | 0.78 | GPR84 (0.47) | GPR84KMT2AHCAR2 | |
| SCHEMBL10244138 | 0.77 | CASP2 (0.49) | GPR84KMT2A | |
| SCHEMBL12598535 | 0.77 | CASP2 (0.49) | GPR84KMT2A | |
| SCHEMBL28063353 | 0.76 | GPR84 (0.49) | GPR84 | |
| SCHEMBL25772018 | 0.76 | GPR84 (0.49) | GPR84KMT2AHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368517-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | UNIV LEUVEN KATH (BE) | 2023-07-05 | — | — | EP | claimed |
| US-10807960-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-10-20 | — | — | US | claimed |
| US-20180305321-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2018-10-25 | — | — | US | claimed |
| EP-3368517-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | Katholieke Universiteit Leuven (BE) | 2018-09-05 | — | — | EP | claimed |
| WO-2017070755-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-05-04 | — | — | WO | claimed |
| EP-3368517-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | UNIV LEUVEN KATH (BE) | 2023-07-05 | — | — | EP | disclosed |
| US-10807960-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-10-20 | — | — | US | disclosed |
| US-10807960-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-10-20 | — | — | US | disclosed |
| US-20180305321-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2018-10-25 | — | — | US | disclosed |
| US-20180305321-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2018-10-25 | — | — | US | disclosed |
| EP-3368517-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | Katholieke Universiteit Leuven (BE) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368517-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | Katholieke Universiteit Leuven (BE) | 2018-09-05 | — | — | EP | disclosed |
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2708538-A1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2014-03-19 | — | — | EP | disclosed |
| EP-2411393-B1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8623880-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| EP-2411393-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010125469-A1 | PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010109287-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305321-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | AADAC, TYR, HAAO | GPR84 3544/4885AOC3 1296/4885KMT2A 1012/4885 |
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | GPR84 112/4885AOC3 2895/4885KMT2A 4283/4885 |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | GPR84 85/4885AOC3 3432/4885KMT2A 4260/4885 |
| US-10807960-B2 | Compounds, compositions, and methods for controlling biofilms | AADAC, TYR, HAAO | GPR84 3544/4885AOC3 1296/4885KMT2A 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.